The global rare gastrointestinal diseases treatment market garnered a market value of USD 1,314.8 million in 2022. The market is set to reach USD 1,353.2 million in 2023 and is expected to register a CAGR of 3.7% from 2023 to 2033. Following this moderate growth rate, the worldwide adoption of gastrointestinal rare disease treatment could accumulate a market value of USD 1,940.6 million by 2033.
The growth of the rare gastrointestinal diseases treatment market can be attributed to increasing awareness of gastrointestinal diseases and the development of various medications.
A rare gastrointestinal disease occurs uncommonly in the overall population. According to the International Rare Diseases Research Consortium (IRDiRC), it is a rare disease that affects less than 1 in 2,000 citizens. Gastrointestinal diseases affect fewer than 200,000 patients in the United States. Yet for the combined population of 800 million, this could range from a few hundred to as many as 400,000 individuals for any rare disease. In addition, government initiatives, funding, and collaboration in rare gastrointestinal disease projects are enhancing the treatment available for the market.
| Report Attributes or Data Points | Details |
|---|---|
| Global Rare Gastrointestinal Diseases Treatment Market Valuation in 2022 | USD 1,314.8 million |
| Estimated Global Market Share in 2023 | USD 1,353.2 million |
| Forecasted Global Market Size by 2033 | USD 1,940.6 million |
| Projected Global Market Growth Rate from 2023 to 2033 | 3.7% CAGR |
| Historical Market Growth Rate from 2018 to 2022 | 2.9% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
In terms of value, the global demand for gastrointestinal rare disease treatment was a mere USD 1,139.9 million in 2018. According to a recent report from FMI, during the historical period between 2018 and 2022, sales witnessed significant growth, registering a year-on-year growth rate of 2.9%.
Gastrointestinal rare disease treatment is available to overcome this life-threatening gastrointestinal rare disease that can help to reduce the impact on the worldwide diseased population. New therapies developed and approved by the specific regulatory authority can improve the quality and quantity of life.
Global cooperation and collaboration amongst scientists, researchers, companies, and government authorities create the opportunity to make new therapies for rare disease treatments.
Increasing awareness regarding treatments, along with the development of different methods of medicine, is accelerating the demand for the same. Improving healthcare systems, technology to detect gastrointestinal diseases, and immediate relief positively influences the demand for the gastrointestinal treatment market.
Rising Prevalence of Gastrointestinal Diseases Increasing Dependency on Treatment
Collectively, around 30 million people are living with a rare disease in the United States and another 3.5 million in the United Kingdom. Around the globe, the rare disease community is estimated to include 350 million people, creating a huge opportunity expected to boost the gastrointestinal rare disease treatment market during the forecast period.
Gastrointestinal diseases related to the small intestine, diarrhea, and irritable bowel syndrome affect populations of different age groups. This has led to most people seeking treatment for these ailments. Moreover, the availability of medication and nutrition treatments supports the growth of the market.
Awareness and Government Initiatives are Driving the Growth of the Rare Gastrointestinal Diseases Market
An increase in government initiative and funding, capital venture funding raised by various investors, and reimbursement policy improvements are the key drivers for the rare gastrointestinal diseases treatment market. Collaboration among physician, researcher, and manufacturers also boost the market growth for gastrointestinal rare disease treatment.
Researchers are studying the growth of bacteria in the intestines along with producing different medicines for the gastrointestinal conditions. This has led to a plethora of options for treatments. Moreover, increasing awareness regarding gastrointestinal diseases amongst people is driving the growth of the rare gastrointestinal diseases treatment market.
Principal Consultant
Lack of Awareness Restraining Gastrointestinal Rare Disease Treatment Market Growth
Lack of awareness causes a delay in the diagnosis of rare gastrointestinal diseases. In addition, the third-world category of orphan drugs has resulted in scarce commercial interest for private investors. Furthermore, a lack of regulatory framework in emerging countries combined with a lack of skilled healthcare personnel could be a crucial restraint for the rare gastrointestinal diseases treatment market.
Furthermore, each faces unique gastrointestinal disease problems. This has led to treating patients with different methods. Although research is underway for developing treatments, only some treatments can suit one. These factors are affecting the gastrointestinal rare disease treatment market.
| Regional Market Comparison | Global Market Share in Percentage |
|---|---|
| North America | 39.5% |
| Europe | 28.3% |
Government Initiatives Supporting the Growth of Gastrointestinal Treatments in the Region
North America dominates in the treatment of rare gastrointestinal diseases. It may continue to dominate the global market because of the increase in patients having rare gastrointestinal diseases. This can be attributed to unprecedented changes in lifestyle, resulting in stomach ulcers, bleeding, hemorrhoids, and anemia, among others.
Moreover, the presence of government initiatives aimed at preventing as well as treating gastrointestinal diseases is expected to drive the market.
For instance, the Integrated Global Action Plan for Diarrhea by UNICEF and WHO aims to minimize preventable childhood deaths due to diarrhea by providing interventions and services to raise awareness and provide access to treatment and preventive measures. Thus, North America held more than 39.5% market share for the rare gastrointestinal diseases treatment market in 2022.
| Regional Market Comparison | Global Market Share in Percentage |
|---|---|
| United States | 34.7% |
| Germany | 7.6% |
| Japan | 3.9% |
Technological Graduation, along with the Immediate Requirement for Treatment, Drives Market Growth
Europe is anticipated to exhibit exponential growth throughout the forecast period. This is likely to be fueled by consistent efforts undertaken by key players, which include research and development investments as well as commercialization of branded drugs at a relatively lower price.
In addition, the urgent need to curb the high incidence rate of gastrointestinal disorders and the technological gradation of healthcare infrastructure are predicted to present the regional market with high potential growth opportunities over the forecast period. Thus, Europe possessed almost 28.3% of the global market share for the rare gastrointestinal diseases treatment market in 2022.
| Regional Markets | CAGR (2023 to 2033) |
|---|---|
| United Kingdom | 2.8% |
| China | 4.9% |
| India | 4% |
| Australia | 3.6% |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Technologically Advanced Equipment Attracting Patients to Hospitals
Development of the healthcare sector by technology and innovation is boosting the demand for the rare gastrointestinal disease treatment market. Moreover, technologically advanced machines for diagnosing various components related to gastrointestinal issues are offering solutions at the earliest.
In addition, the rapid adoption of undertaking tests by patients and hospitals possessing the adequate equipment to carry tests is accelerating the growth of hospitals in the market. Thus, by the end user, hospitals possessed nearly 41.4% of the global market share for the rare gastrointestinal diseases treatment market in 2022.
| Category | By Treatment |
|---|---|
| Top Segment | Medication |
| Market Share in Percentage | 54.2% |
| Category | By End User |
|---|---|
| Top Segment | Hospitals |
| Market Share in Percentage | 41.4% |
Drug Discovery, Targeted Medicines, and Creative Treatment Methods Have all Advanced Significantly in the Pharmaceutical Industry
Pharmaceutical firms are investing in research and development to provide medicines targeting the underlying causes of rare gastrointestinal illnesses. It is gaining a lot of interest from healthcare professionals since they frequently aim to relieve symptoms and delay the course of the disease.
A sizable pool of patients with rare gastrointestinal diseases was generated due to the rise in diagnoses in the last few years. Medications target certain biological pathways and illness processes to treat each patient more effectively and personally. Thus, the possibility for better results and fewer adverse effects has made the medication approach more popular than nutritional methods.
Key start-up players in the rare gastrointestinal diseases treatment market are Synergy Pharmaceuticals, Ventyx Biosciences, Metacrine, Capso Vision, and Ritter Pharmaceuticals.
Key players in the market include Bayer Pharmaceutical Corp, Teva Pharmaceutical, Novartis AG, Sanofi, Pfizer, Inc., GlaxoSmithKline PLC, Eli Lilly and CO., Johnson & Johnson, and others.
| Report Attribute | Details |
|---|---|
| Market Value in 2022 | USD 1,314.8 million |
| Market Value in 2033 | USD 1,940.6 million |
| Growth Rate | CAGR of 3.7% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered | Treatment Type, End User, Region |
| Regions Covered | North America; Latin America; Western Europe; Eastern Europe; APEJ; Japan; The Middle East and Africa |
| Key Countries Profiled | United States, Canada, Brazil, Argentina, Germany, United Kingdom, France, Spain, Italy, Nordics, BENELUX, Australia & New Zealand, China, India, ASEAN, GCC, South Africa |
| Key Companies Profiled | Bayer Pharmaceutical Corp; Teva Pharmaceutical; Novartis AG; Sanofi; Pfizer, Inc.; GlaxoSmithKline PLC; Eli Lilly and CO.; Johnson & Johnson |
| Customization | Available Upon Request |
A market value of USD 1,353.2 million is expected in 2023.
The CAGR for North America between 2018 and 2022 was 39.5%.
By 2033, the market is expected to reach USD 1,940.6 million.
Medications will account for 54.2% of the market in 2023.
Growth in China is steady at 4.9% between 2023 and 2033.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment Type 5.1. Rare Gastrointestinal Diseases Treatment 5.2. Rare Gastrointestinal Diseases Treatment 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User 6.1. Rare Gastrointestinal Diseases Treatment 6.2. in Research Institutes 6.3. in Other End User Settings 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. North America 7.2. Latin America 7.3. Western Europe 7.4. Eastern Europe 7.5. South Asia and Pacific 7.6. East Asia 7.7. Middle East and Africa 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. Key Countries Market Analysis 16. Market Structure Analysis 17. Competition Analysis 17.1. Bayer Pharmaceutical Corp 17.2. Teva Pharmaceutical 17.3. Novartis AG 17.4. Sanofi 17.5. Pfizer, Inc. 17.6. GlaxoSmithKline PLC 17.7. Eli Lilly and Co. 17.8. Johnson & Johnson 17.9. F. Hoffmann-La Roche Ltd. 17.10. AstraZeneca 18. Assumptions & Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports
Rare Gastrointestinal Diseases Treatment Market
